Jump to ContentJump to Main Navigation

Since more than 50 years!

Radiochimica Acta

International Journal for chemical aspects of nuclear science and technology

Ed. by Qaim, Syed M.

12 Issues per year

IMPACT FACTOR 2012: 1.373
5-year IMPACT FACTOR: 1.424
Rank 6 out of 34 in category Nuclear Science & Technology in the 2012 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Feasibility studies for production of 89Sr in the Fast Breeder Test Reactor (FBTR)

Debasish Saha1 / J. Vithya1 / G. V. S. Ashok Kumar1 / K. Swaminathan1 / R. Kumar1 / 1 / P. R. Vasudeva Rao1

1Fuel Chemistry Division, Chemistry Group, Indira Gandhi Centre for Atomic Research (IGCAR), Kalpakkam-603102, India

Citation Information: Radiochimca Acta. Volume 101, Issue 10, Pages 667–673, ISSN (Online) 2193-3405, ISSN (Print) 0033-8230, DOI: 10.1524/ract.2013.2055, October 2013

Publication History:
Published Online:
2013-10-16

Summary

89Sr, a pure beta emitter with half life of 50.53 d is used as its chloride solution for palliative care of bone metastases. This paper describes the feasibility studies that have been conducted at FBTR, IGCAR for production of this radionuclide using the 89Y(n, p)89Sr reaction. Yttria pellets were irradiated in a special subassembly at the core centre for a total of 73 d in two steps of 35 d and 38 d with a time gap of 38 d. The irradiated yttria target was dissolved in nitric acid and the bulk Y was separated by solvent extraction using the TBP-HNO3 complex. The 89Sr fraction was purified using the cation exchange resin DOWEX 50W×8 (100-200 mesh size) from the other radioactive impurities seen. The eluted 89Sr fraction was assayed using a GM counting system. The 89Sr activity produced in 1 g of yttria pellet was found to be 19 mCi.

Keywords : 89Sr production; FBTR; Bone pain palliation; Sr-Y; Dissolution of Y2O3 pellet; TBP-HNO3; Ion exchange; GM counter

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.